ARIAD
Pharmaceuticals ARIA today announced updated
clinical results on its investigational tyrosine kinase inhibitor (TKI), AP26113,
in patients with advanced non-small cell lung cancer (NSCLC) from an
ongoing Phase 1/2 trial. These study results show robust anti-tumor
activity of AP26113 in patients with TKI-naïve and crizotinib-resistant
anaplastic lymphoma kinase positive (ALK+) NSCLC, including in patients
with brain metastases after crizotinib treatment. Crizotinib is the
currently available first-generation ALK inhibitor.
The updated Phase 1/2 results are being presented this morning at the
European Cancer Congress (the 38th ESMO, 32nd ESTRO, 17th ECCO
conference) being held in Amsterdam.
Phase 1/2
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in